ID   MDA-MB-468
AC   CVCL_0419
SY   MDA-MB 468; MDA-MB468; MDAMB468; MDA-468; MDA468; MB468; MD Anderson-Metastatic Breast-468
DR   BTO; BTO:0001570
DR   CLO; CLO_0007641
DR   EFO; EFO_0001216
DR   MCCL; MCC:0000316
DR   CLDB; cl4973
DR   AddexBio; C0006003/4673
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-6647
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   ATCC; HTB-132
DR   BCRJ; 0166
DR   BioSample; SAMN03473056
DR   BioSample; SAMN05292454
DR   BioSample; SAMN10988340
DR   CCLE; MDAMB468_BREAST
DR   CCRID; 3111C0001CCC000249
DR   CCRID; 3131C0001000700120
DR   Cell_Model_Passport; SIDM00628
DR   ChEMBL-Cells; CHEMBL3308424
DR   ChEMBL-Targets; CHEMBL614335
DR   CLS; 300279/NA
DR   Cosmic; 809241
DR   Cosmic; 850823
DR   Cosmic; 871149
DR   Cosmic; 877448
DR   Cosmic; 897427
DR   Cosmic; 904384
DR   Cosmic; 908123
DR   Cosmic; 923061
DR   Cosmic; 934530
DR   Cosmic; 949192
DR   Cosmic; 991327
DR   Cosmic; 997921
DR   Cosmic; 1000125
DR   Cosmic; 1010920
DR   Cosmic; 1017167
DR   Cosmic; 1018467
DR   Cosmic; 1046929
DR   Cosmic; 1044224
DR   Cosmic; 1047691
DR   Cosmic; 1136363
DR   Cosmic; 1152526
DR   Cosmic; 1176635
DR   Cosmic; 1287918
DR   Cosmic; 1289402
DR   Cosmic; 1305384
DR   Cosmic; 1309004
DR   Cosmic; 1477427
DR   Cosmic; 1523775
DR   Cosmic; 1524344
DR   Cosmic; 1571795
DR   Cosmic; 1603223
DR   Cosmic; 1609465
DR   Cosmic; 1998490
DR   Cosmic; 2009514
DR   Cosmic; 2036673
DR   Cosmic; 2164999
DR   Cosmic; 2301533
DR   Cosmic; 2318380
DR   Cosmic; 2361357
DR   Cosmic; 2668276
DR   Cosmic-CLP; 908123
DR   DepMap; ACH-000849
DR   DSMZ; ACC-738
DR   GDSC; 908123
DR   GEO; GSM75169
DR   GEO; GSM185095
DR   GEO; GSM185096
DR   GEO; GSM217591
DR   GEO; GSM219929
DR   GEO; GSM344356
DR   GEO; GSM344406
DR   GEO; GSM350502
DR   GEO; GSM388214
DR   GEO; GSM421880
DR   GEO; GSM459714
DR   GEO; GSM459722
DR   GEO; GSM466357
DR   GEO; GSM783955
DR   GEO; GSM847418
DR   GEO; GSM847497
DR   GEO; GSM887301
DR   GEO; GSM888376
DR   GEO; GSM1008911
DR   GEO; GSM1053727
DR   GEO; GSM1172984
DR   GEO; GSM1214565
DR   GEO; GSM1238123
DR   GEO; GSM1374663
DR   GEO; GSM1374664
DR   GEO; GSM1374665
DR   GEO; GSM1401650
DR   GEO; GSM1556177
DR   GEO; GSM1556178
DR   GEO; GSM1556179
DR   GEO; GSM1556180
DR   GEO; GSM1556181
DR   GEO; GSM1661984
DR   GEO; GSM1670087
DR   GEO; GSM1833629
DR   GEO; GSM2124671
DR   IARC_TP53; 94
DR   IBRC; C10095
DR   ICLC; HTL99024
DR   KCB; KCB 2011114YJ
DR   LiGeA; CCLE_336
DR   LINCS_HMS; 50335
DR   LINCS_LDP; LCL-1471
DR   Lonza; 809
DR   NCBI_Iran; C208
DR   NCI-DTP; MDA-MB-468
DR   PharmacoDB; MDAMB468_907_2019
DR   PRIDE; PXD001680
DR   PRIDE; PXD005295
DR   TOKU-E; 2401
DR   TOKU-E; 3604
DR   Wikidata; Q16880225
RX   CelloPub=CLPUB00423;
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=730202;
RX   PubMed=3518877;
RX   PubMed=9671407;
RX   PubMed=11414198;
RX   PubMed=12353263;
RX   PubMed=12800145;
RX   PubMed=15677628;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=18262045;
RX   PubMed=18516279;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=20070913;
RX   PubMed=20164919;
RX   PubMed=21778573;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=22628656;
RX   PubMed=23151021;
RX   PubMed=23601657;
RX   PubMed=23856246;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=24279929;
RX   PubMed=25485619;
RX   PubMed=25699542;
RX   PubMed=25960936;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=28287265;
RX   PubMed=28889351;
RX   PubMed=30613774;
RX   PubMed=30787054;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32576280;
WW   https://en.wikipedia.org/wiki/MDA-MB-468
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://physics.cancer.gov/docs/bioresource/breast/NCI-PBCF-HTB132_MDA-MB-468_v1.0_SOP-508.pdf
WW   http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/mda-mb-468.html
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-468
WW   http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-53.html
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=249
WW   http://www.cellresource.cn/fdetail.aspx?id=688
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Doubling time: 40.6 hours (PubMed=32576280); 62 hours (NCI-DTP); ~30-40 hours (DSMZ); ~47 hours (PBCF); 79.76 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   HLA typing: A*30:02,23:01; B*27:03,53:01; C*02:02,04:01 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (PubMed=15677628; Sanger).
CC   Sequence variation: Homozygous for PTEN c.253+1G>T; splice donor mutation (PubMed=19593635).
CC   Sequence variation: Homozygous for RB1 c.265_2787del2523 (PubMed=19593635).
CC   Sequence variation: Homozygous for TP53 p.Arg273His (c.818G>A) (ClinVar=VCV000012366) (PubMed=16541312; PubMed=28889351; ATCC).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=80.3%; Native American=0%; East Asian, North=6.19%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=13.51% (PubMed=30894373).
CC   Discontinued: CLS; 300279; true.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; PubMed=25877200; PubMed=28889351
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 17
ST   D19S433: 12,13
ST   D21S11: 27 (CCRID)
ST   D21S11: 27,28 (PubMed=25877200; PubMed=28889351)
ST   D2S1338: 17,25
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 8
ST   D8S1179: 13
ST   FGA: 23
ST   Penta D: 8,10
ST   Penta E: 5
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 18
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 35
//
RX   CelloPub=CLPUB00423;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010), Griffith University, Australia.
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
//
RX   PubMed=730202; DOI=10.1007/BF02616120;
RA   Cailleau R.M., Olive M., Cruciger Q.V.J.;
RT   "Long-term human breast carcinoma cell lines of metastatic origin:
RT   preliminary characterization.";
RL   In Vitro 14:911-915(1978).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=9671407; DOI=10.1038/sj.onc.1201814;
RA   Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.;
RT   "Lack of relationship between CDK activity and G1 cyclin expression in
RT   breast cancer cells.";
RL   Oncogene 16:2865-2878(1998).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=12353263; DOI=10.1002/gcc.10107;
RA   Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J.,
RA   Mozziconacci M.-J., Conte N., Murati A., Ginestier C.,
RA   Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C.,
RA   Birnbaum D., Chaffanet M.;
RT   "Reciprocal translocations in breast tumor cell lines: cloning of a
RT   t(3;20) that targets the FHIT gene.";
RL   Genes Chromosomes Cancer 35:204-218(2002).
//
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=18262045; DOI=10.1016/j.cancergencyto.2007.05.030;
RA   Xu J., Chambers A.F., Tuck A.B., Rodenhiser D.I.;
RT   "Molecular cytogenetic characterization of human breast cancer cell
RT   line MDA-MB-468 and its variant 468LN, which displays aggressive
RT   lymphatic metastasis.";
RL   Cancer Genet. Cytogenet. 181:1-7(2008).
//
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A.,
RA   Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=20070913; DOI=10.1186/1471-2407-10-15;
RA   Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M.,
RA   Yamamoto S., Oka M., Hirano T., Sasaki K.;
RT   "Breast cancer cell lines carry cell line-specific genomic alterations
RT   that are distinct from aberrations in breast cancer tissues:
RT   comparison of the CGH profiles between cancer cell lines and primary
RT   cancer tissues.";
RL   BMC Cancer 10:15-15(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21778573; DOI=10.3233/BD-2010-0307;
RA   Chavez K.J., Garimella S.V., Lipkowitz S.;
RT   "Triple negative breast cancer cell lines: one tool in the search for
RT   better treatment of triple negative breast cancer.";
RL   Breast Dis. 32:35-48(2010).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619-619(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33-R33(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L.,
RA   Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L.,
RA   Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J.,
RA   Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20-20(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25699542; DOI=10.15252/msb.20145664;
RA   Muellner M.K., Mair B., Ibrahim Y., Kerzendorfer C., Lechtermann H.,
RA   Trefzer C., Klepsch F., Muller A.C., Leitner E., Macho-Maschler S.,
RA   Superti-Furga G., Bennett K.L., Baselga J., Rix U., Kubicek S.,
RA   Colinge J., Serra V., Nijman S.M.B.;
RT   "Targeting a cell state common to triple-negative breast cancers.";
RL   Mol. Syst. Biol. 11:789-789(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20-20(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//
RX   PubMed=30613774; DOI=10.1126/sciadv.aau7314;
RA   Vande Voorde J., Ackermann T., Pfetzer N., Sumpton D., Mackay G.,
RA   Kalna G., Nixon C., Blyth K., Gottlieb E., Tardito S.;
RT   "Improving the metabolic fidelity of cancer models with a
RT   physiological cell culture medium.";
RL   Sci. Adv. 5:Eaau7314-Eaau7314(2019).
//
RX   PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132;
RA   Hooker S.E., Woods-Burnham L., Bathina M., Lloyd S.M., Gorjala P.,
RA   Mitra R., Nonn L., Kimbro K.S., Kittles R.;
RT   "Genetic ancestry analysis reveals misclassification of commonly used
RT   cancer cell lines.";
RL   Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32576280; DOI=10.1186/s13058-020-01300-y;
RA   Finlay-Schultz J., Jacobsen B.M., Riley D., Paul K.V., Turner S.,
RA   Ferreira-Gonzalez A., Harrell J.C., Kabos P., Sartorius C.A.;
RT   "New generation breast cancer cell lines developed from
RT   patient-derived xenografts.";
RL   Breast Cancer Res. 22:68-68(2020).
//